eNewsroom for: Avillion LLP

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Avillion LLP/Screen-Shot-2013-05-28-at-11.29.07-AM.png

Avillion LLP Company Profile

Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products. We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market. Avillion is staffed with a team of expert professionals with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis. Our offices are in London, United Kingdom, and we are financed by our international investors, Abingworth and Clarus Ventures.

News from Avillion LLP:

Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

LONDON, Jan. 9, 2014 /PRNewswire/ — The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's BOSULI…

Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer

LONDON, May 28, 2013 /PRNewswire/ – Avillion LLP, which focuses on clinical co-development of therapeutics, today announced the expansion of its leadership team with the appointment of Ramani Varanasi, MSc, MBA, as Chief Business Officer.
Ramani is an accomplished business executive, bri…